The Trump administration is probing the impact of pharmaceutical imports on national security, potentially leading to tariffs on both branded and generic medicines. The investigation, launched by the Department of Commerce under Section 232, aims to assess whether domestic production can satisfy demand and the feasibility of increasing local manufacturing. While some pharmaceutical companies are planning significant investments in U.S. production, analysts warn that tariffs could escalate costs and restrict R&D funding, particularly affecting generic manufacturers with tighter margins. Comments on the plans are being sought, with potential tariffs expected within months.

Source: https://www.supplychaindive.com/news/trump-tariffs-pharma-section-232-investigation-commerce/745342/